Paul Matteis of Stifel, Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold and Decreased Target from $244 to $213 on, Sep 9th, 2021.
Paul has made no other calls on VRTX in the last 4 months.
There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Danielle Brill of "Raymond James" Initiated at Hold on, Thursday, July 1st, 2021
These are the ratings of the 11 analyists that currently disagree with Paul
- Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021
- Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Sunday, August 1st, 2021
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $248 on, Friday, July 30th, 2021
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $323 on, Friday, July 30th, 2021
- Geoffrey Porges of "SVB Leerink" Maintained at Sell with Increased Target to $175 on, Friday, July 30th, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $331 on, Monday, June 14th, 2021
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $307 on, Friday, June 11th, 2021
- Mohit Bansal of "Citigroup" Maintained at Strong Buy with Decreased Target to $285 on, Friday, June 11th, 2021
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $285 on, Friday, June 11th, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $281 on, Friday, June 11th, 2021
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $279 on, Wednesday, May 12th, 2021
